LAVAL, Que. – Valeant Pharmaceuticals International announced Wednesday that Deb Jorn has resigned as executive vice-president, company group chairman, effective immediately.

Jorn was responsible for running Valeant’s U.S. dermatology and gastrointestinal businesses.

Eric Abramson, vice-president dermatology & immunology marketing, has been appointed general manager of the U.S. dermatology business and Dr. Ari Kellen, executive vice-president and company group chairman, will oversee Valeant’s gastrointestinal business.

Valeant is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics.

Valeant Pharmaceuticals announced Monday that it is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe.

In a brief statement, the Quebec-based drugmaker confirmed it received a subpoena from the commission in the fourth quarter of 2015. The company said it would have disclosed the investigation when filing audited full-year results, but those have been delayed.

Valeant declined further comment. The commission also declined comment.

Valeant closed at $90.76 Wednesday on the Toronto Stock Exchange. At its peak last summer, the stock was trading above $346.